CO6531414A2 - Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos - Google Patents

Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos

Info

Publication number
CO6531414A2
CO6531414A2 CO12046249A CO12046249A CO6531414A2 CO 6531414 A2 CO6531414 A2 CO 6531414A2 CO 12046249 A CO12046249 A CO 12046249A CO 12046249 A CO12046249 A CO 12046249A CO 6531414 A2 CO6531414 A2 CO 6531414A2
Authority
CO
Colombia
Prior art keywords
aptamers
disorders
tfpi
hemorrhagical
treatment
Prior art date
Application number
CO12046249A
Other languages
English (en)
Spanish (es)
Inventor
Robert G Schaub
Kathleen Mcginness
Jennifer Nelson
Ryan Genga
Emilly Waters
John L Diener
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Publication of CO6531414A2 publication Critical patent/CO6531414A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO12046249A 2009-08-18 2012-03-16 Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos CO6531414A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23493909P 2009-08-18 2009-08-18
US35337410P 2010-06-10 2010-06-10
US36636210P 2010-07-21 2010-07-21
US36776610P 2010-07-26 2010-07-26

Publications (1)

Publication Number Publication Date
CO6531414A2 true CO6531414A2 (es) 2012-09-28

Family

ID=43607310

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12046249A CO6531414A2 (es) 2009-08-18 2012-03-16 Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos

Country Status (17)

Country Link
US (1) US8252913B2 (enExample)
EP (1) EP2467167B1 (enExample)
JP (1) JP2013502218A (enExample)
KR (1) KR20120061086A (enExample)
CN (1) CN102869385A (enExample)
AU (1) AU2010284329B2 (enExample)
BR (1) BR112012003806A2 (enExample)
CA (1) CA2770762A1 (enExample)
CO (1) CO6531414A2 (enExample)
ES (1) ES2655589T3 (enExample)
IL (1) IL218048A0 (enExample)
IN (1) IN2012DN01984A (enExample)
MX (1) MX2012002133A (enExample)
NZ (1) NZ598557A (enExample)
RU (1) RU2012110221A (enExample)
SG (1) SG178408A1 (enExample)
WO (1) WO2011022427A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070166741A1 (en) 1998-12-14 2007-07-19 Somalogic, Incorporated Multiplexed analyses of test samples
US7947447B2 (en) 2007-01-16 2011-05-24 Somalogic, Inc. Method for generating aptamers with improved off-rates
KR101745394B1 (ko) 2008-12-22 2017-06-09 노보 노르디스크 에이/에스 조직 인자 경로 억제자에 대한 항체
EP2673364A1 (en) * 2011-02-11 2013-12-18 Baxter International Inc Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
EP2718430B1 (en) * 2011-06-08 2015-12-09 Miedzynarodowy Instytut Biologii Molekularnej I Komorkowej Sequence-specific engineered ribonuclease h and the method for determining the sequence preference of dna-rna hybrid binding proteins
WO2013142153A2 (en) * 2012-03-22 2013-09-26 Baxter International Inc. Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics
DE102012020496A1 (de) 2012-10-18 2014-04-24 Charité - Universitätsmedizin Berlin Biomarker zur Diagnostik und Behandlung von Neurofibromatose Typ 1
WO2014205426A1 (en) * 2013-06-21 2014-12-24 Imigene, Inc. Blood analysis
US10457743B2 (en) 2013-07-19 2019-10-29 Novo Nordisk A/S Antibodies recognizing the N-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
CA3221709A1 (en) * 2013-09-09 2015-03-12 Somalogic Operating Co., Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
US11181534B2 (en) 2014-04-04 2021-11-23 Bloodworks Routine laboratory and point-of-care (POC) testing for hemostasis
PT3313991T (pt) * 2015-06-23 2024-09-27 Childrens Hospital Philadelphia Fator ix modificado e composições, métodos e utilizações para transferência de genes para células, órgãos e tecidos
WO2017062536A2 (en) * 2015-10-06 2017-04-13 Kieu Hoang A method of manfacturing prothrombin complex concentrate from fraction iii and non-prothrombin complex concentrate from fraction iv
AU2016364431B2 (en) 2015-12-04 2020-08-27 Zenyaku Kogyo Co., Ltd. Anti-IL-17 aptamer having improved retention in blood
CN112442127A (zh) * 2019-08-29 2021-03-05 苏州康宁杰瑞生物科技有限公司 针对tfpi的单克隆抗体
CN115792231B (zh) * 2022-11-04 2023-07-25 中拓生物有限公司 一种基于凝血酶适配体调节的酶级联反应的DNase I生物传感器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5981471A (en) * 1997-02-06 1999-11-09 Entremed, Inc. Compositions and methods for inhibiting cellular proliferation
AU738513B2 (en) 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
EP1872786A1 (en) 1997-09-05 2008-01-02 The Regents of the University of California Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
DE69940623D1 (de) 1998-11-09 2009-04-30 Eiken Chemical Prozess zur Synthetisierung von Nukleinsäure
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
AU2003238772A1 (en) * 2002-05-31 2003-12-19 Regents Of The University Of Minnesota In vitro evaluation of nucleic acid ligands
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20080161425A1 (en) * 2005-07-29 2008-07-03 Universiteit Van Maastricht Regulation of Tissue Factor Activity by Protein S and Tissue Factor Pathway Inhibitor

Also Published As

Publication number Publication date
BR112012003806A2 (pt) 2016-11-16
US20110098345A1 (en) 2011-04-28
RU2012110221A (ru) 2013-09-27
CN102869385A (zh) 2013-01-09
IN2012DN01984A (enExample) 2015-07-24
AU2010284329B2 (en) 2015-04-16
IL218048A0 (en) 2012-04-30
CA2770762A1 (en) 2011-02-24
WO2011022427A1 (en) 2011-02-24
JP2013502218A (ja) 2013-01-24
NZ598557A (en) 2013-08-30
US8252913B2 (en) 2012-08-28
KR20120061086A (ko) 2012-06-12
EP2467167A1 (en) 2012-06-27
ES2655589T3 (es) 2018-02-20
SG178408A1 (en) 2012-03-29
MX2012002133A (es) 2013-02-15
AU2010284329A1 (en) 2012-03-29
EP2467167B1 (en) 2017-08-16
EP2467167A4 (en) 2013-12-25

Similar Documents

Publication Publication Date Title
CO6531414A2 (es) Aptámeros del inhibidor de la vía del factor tisular y sus usos como tratamiento de trastornos hemorrágicos
DOP2019000287A (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi)
CO6620068A2 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi)
CY1119596T1 (el) Σταθερη φαρμακευτικη συνθεση και μεθοδοι χρησης αυτης
MX370599B (es) Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
GT201400166A (es) Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca
UY31858A (es) 3-metil-7-(2-butin-1-il)-8-(3-(r)-amino-piperidin-1-il)-xantinas y sus sales farmacéuticamente aceptables como inhibidores de dpp-4 para aplicaciones terapéuticas
MX2013001362A (es) Inmunoglubinas de dominio variable doble y usos de las mismas.
GT200600297A (es) Nuevos anticuerpos anti-madcam
UY32965A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
DOP2012000265A (es) Proteína de fusión robo1-fc y su utilización en el tratamiento de tumores.
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CO6690781A2 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ECSP13012648A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
UY33707A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2013003282A (es) Materiales y metodos para mejorar la funcion gastrointestinal.
CR20120248A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
MX2016006271A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
BR112015001782A2 (pt) método para produzir uma composição para o tratamento de um dente lesionado
BR112015015108A2 (pt) cateter com marcações para facilitar o alinhamento
MX376473B (es) Composicion para tratar lesiones cerebrales.
GT201300125A (es) 1h-pirazol-5-olato sódico sustituido
UY35745A (es) Derivados sustituidos de fenilalanina
UY37622A (es) Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas